Efficacy and Safety of Ultrapulse Carbon Dioxide Laser Treatment in Eyelid Tumors

Launched by SUN YAT-SEN UNIVERSITY · Jan 4, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at the effectiveness and safety of a specific laser treatment, called ultrapulse carbon dioxide (CO₂) laser excision, for various types of eyelid tumors. These include conditions like xanthelasma (yellowish growths), pigmented nevi (moles), and keratoses (thickened skin). The goal is to see how well this treatment works over the long term and to ensure it is safe for patients.

To participate, individuals must be diagnosed with one of these eyelid conditions and should not have certain health issues, such as allergies to lidocaine (a numbing medication) or a tendency to develop keloids (thick, raised scars). Participants should also be able to attend follow-up appointments to monitor their recovery. If you or a loved one are interested, this trial is currently recruiting patients aged between 6 and 80 years and welcomes individuals of any gender. Overall, this study could provide important information about a new treatment option for eyelid tumors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinically diagnosed with eyelid lesions, including xanthelasma, pigmented nevi, keratoses, and so on.
• • No history of photosensitivity, bleeding, or coagulation disorders
• • Willing to attend follow-up appointments as scheduled
• Exclusion Criteria:
• • Presence of infection in the target area
• • Allergy to lidocaine
• • Keloid-prone or poor skin repair ability
• • Pregnant or lactating
• • Recent history of severe infectious diseases, active skin diseases, or major diseases affecting the cardiovascular, liver, kidney, endocrine, and hematopoietic systems
• • History of malignant tumors or immune system disorders